Characteristics of Studies Eligible for Metaanalysis
| Study | Country | Data type | Study design | Device | Lymphoma subtype | Patients (n) | 18F-FDG dose (MBq/kg) | Gold standard |
| Agrawal (35) | India | Patients | Retrospective | PET/CT | HL | 38 | 3.7 | Follow-up and CT |
| Bakhshi (38) | India | Patients | Prospective | PET/CT | NHL | 34 | 6–7 | Follow-up imaging |
| Cheng (36) | USA | Patients | Retrospective | PET/CT | HL&NHL | 54 | 5.18 | Pathologic and clinical follow-up |
| Depas (43) | Belgium | Patients | Retrospective | PET | HL&NHL | 28 | 3.7 or 2.2 | Pathologic and clinical follow-up |
| Furth (85) | Germany | Patients | Prospective | PET | HL | 40 | NA | Pathologic, clinical, and imaging follow-up |
| Ilivitzki (45) | Israel | Patients | Prospective | PET/CT | HL | 34 | 5.3 | Follow-up 18F-FDG PET |
| Lopci (132) | Italy | Patients | Prospective | PET | HL&NHL | 20 | 5.3 | Histopathologic and clinical follow-up |
| Meany (51) | USA | Patients | Retrospective | PET/CT? | HL | 23 | NA | Histopathologic, clinical, biochemical, and radiographic evaluation |
| Miller (14) | Israel | Patients | Retrospective | PET/CT | HL&NHL | 31 | 7.4 | Follow-up imaging |
| Purz (37) | Germany | Patients | Prospective | PET and PET/CT? | HL | 175 | NA | Bone marrow biopsy, MR imaging, CT, and clinical follow-up |
| Riad (26) | Egypt | Patients | Retrospective | PET/CT | HL&NHL | 152 | 3.7 | Pathologic and clinical follow-up |
NA = data not available.